Normal Ex Vivo Mesenchymal Stem Cell Function Combined with Abnormal Immune Profiles Sets the Stage for Informative Cell Therapy Trials in Idiopathic Pulmonary Fibrosis Patients

Scientists characterized the functionality of autologous MSCs for use as an idiopathic pulmonary fibrosis therapy and presented an attempt to determine whether the disease occurring in the lungs was associated with an alterated immune system.